Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma

• Published in: Cancers 2021-12, Vol.14 (1), p.205
• Main Authors: Ly, Dalam, Li, Quan, Navab, Roya, Zeltz, Cédric, Fang, Linan, Cabanero, Michael, Zhu, Chang-Qi, Tsao, Ming-Sound, Zhang, Li
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Antitumor activity; Blood; CD4 antigen; Cell adhesion & migration; Collagen; Collagen (type I); Datasets; Extracellular matrix; Foxp3 protein; Gene expression; Genetic analysis; Immune system; Immunoregulation; Immunosuppressive agents; Immunotherapy; Leukocytes; Lung cancer; Lymphocytes; Lymphocytes T; Medical prognosis; Patients; Stroma; Transcription; Tumor cells; Tumor microenvironment; Tumor-infiltrating lymphocytes; Tumorigenesis
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14010205

Cancer development requires a permissive microenvironment that is shaped by interactions between tumor cells, stroma, and the surrounding matrix. As collagen receptors, the leukocyte-associated immunoglobulin-like receptor (LAIR) family allows the immune system to interact with the extracellular matrix. However, little is known about their role in regulating tumor immunity and cancer progression. Genetic analysis of resected human lung adenocarcinoma was correlated to clinical-pathological characteristics, gene ontologies, and single cell RNA sequencing (scRNASeq). LAIR2 production was determined in subsets of immune cells isolated from blood leukocytes and lung adenocarcinoma tumor. Functional assays were used to determine the role of LAIR2 in tumorigenesis. expression was adversely prognostic in lung adenocarcinoma. LAIR2 was preferentially produced by activated CD4 T cells and enhanced in vitro tumor invasion into collagen. scRNASeq analysis of tumor infiltrating T cells revealed that expression co-localized with FOXP3 expressing cells and shared a transcriptional signature with tumor-associated regulatory T (T ) cells. A CD4 LAIR2 T gene signature was prognostically significant in the TCGA dataset ( = 439; hazard ratio (HR) = 1.37; 95% confidence interval (CI), 1.05-1.77, = 0.018) and validated in NCI Director's Challenge lung adenocarcinoma dataset ( = 488; HR = 1.54; 95% CI, 1.14-2.09, = 0.0045). Our data support a role for LAIR2 in lung adenocarcinoma tumorigenesis and identify a CD4 LAIR2 T gene signature in lung adenocarcinoma prognosis. LAIR2 provides a novel target for development of immunotherapies.